ArticleJournal of cancer survivorship : research and practice2025
Survivors' perspectives on cisplatin-induced ototoxicity and barriers to ototoxicity monitoring.
Article in Journal of cancer survivorship : research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeCisplatin-based chemoradiation therapy (CRT) causes ototoxicity in survivors of head and neck (H&N) cancer, but rates of audiologic follow-up are poor. Our objective is to identify (1) QOL domains that are affected by treatment-related ototoxicity and (2) barriers to ototoxicity monitoring among survivors of H&N cancer to inform patient-centered interventions that reduce undiagnosed and untreated ototoxicity in survivorship.
methodsA qualitative study using semi-structured focus groups was conducted from March 2023 to September 2023 on survivors of H&N cancer treated with cisplatin-based CRT at a single tertiary care center. Inductive thematic analysis was used to identify themes related to the effect of ototoxicity on QOL and barriers to ototoxicity monitoring.
resultsSeven focus groups ranging from 1 to 4 participants were conducted on 18 total participants (median age = 58 (range 45-67); 13 (72%) male; 16 (89%) white). Themes regarding ototoxicity and its effects on QOL included (1) social isolation, (2) emotional distress, (3) adaptive behaviors, and (4) that the impact is context-dependent. Themes regarding barriers to ototoxicity monitoring included (5) inconsistent referral to audiology; (6) the lack of patient education; (7) socioeconomic factors; and (8) hesitancy towards hearing aids.
conclusionsTreatment-related ototoxicity has long-term implications for poorer QOL in H&N cancer survivorship. However, the negative impact of ototoxicity changes over time and depends on multiple patient-related factors. IMPLICATIONS FOR CANCER SURVIVORS: Monitoring programs might seek to develop protocols to routinely screen H&N cancer survivors for ototoxicity and provide referrals and patient education material to improve audiologic follow-up. Such protocols may decrease rates of undiagnosed and untreated hearing loss in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.